NCT04423029
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with micro-satellite instability high cancer or triple negative breast cancer are eligible for the expansion cohort – see trial for details
Exclusions: Patients with a history of central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT04423029